Vanguard Personalized Indexing Management LLC Purchases 45,959 Shares of Takeda Pharmaceutical Co. $TAK

Key Points

• Vanguard Personalized Indexing Management LLC increased its stake in Takeda Pharmaceutical by 29.4%, purchasing an additional 45,959 shares for a total of 202,312 shares valued at approximately $3.128 million.
• Multiple institutional investors have also raised their stakes in Takeda Pharmaceutical, contributing to a collective ownership of 9.17% of the company's stock by institutional investors and hedge funds.
• Takeda's stock has a market cap of $44.09 billion and reported $7.45 billion in revenue for the most recent quarter, slightly below analyst forecasts.

Vanguard Personalized Indexing Management LLC boosted its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 29.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 202,312 shares of the company's stock after purchasing an additional 45,959 shares during the period. Vanguard Personalized Indexing Management LLC's holdings in Takeda Pharmaceutical were worth $3,128,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its stake in shares of Takeda Pharmaceutical by 29.2% in the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock valued at $69,000 after acquiring an additional 1,045 shares during the last quarter. GAMMA Investing LLC increased its holdings in Takeda Pharmaceutical by 22.6% during the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock valued at $105,000 after purchasing an additional 1,296 shares in the last quarter. Fifth Third Bancorp raised its position in Takeda Pharmaceutical by 85.5% in the 1st quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after purchasing an additional 2,411 shares during the last quarter. Sagespring Wealth Partners LLC bought a new position in Takeda Pharmaceutical in the 1st quarter valued at $162,000. Finally, QRG Capital Management Inc. boosted its stake in Takeda Pharmaceutical by 17.4% in the first quarter. QRG Capital Management Inc. now owns 386,928 shares of the company's stock worth $5,754,000 after purchasing an additional 57,284 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 0.4%

Shares of NYSE:TAK opened at $13.86 on Thursday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The stock has a market cap of $44.09 billion, a price-to-earnings ratio of 46.18 and a beta of 0.21. The company has a 50 day moving average of $14.83 and a 200-day moving average of $14.77. Takeda Pharmaceutical Co. has a one year low of $12.80 and a one year high of $15.69.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on TAK. Zacks Research cut Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Takeda Pharmaceutical in a research note on Tuesday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold".

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co. (NYSE:TAK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.